The Biomedical Catalyst, a joint program of the UK’s Medical Research Council and the Technology Strategy Board, has awarded a grant of up to £1.3M in matched funding to Prosonix for support of a research consortium focused on pre-clinical development of the Prosonix Multi-Component Particle (MCP) platform for excipient-free inhaled combination drugs. The consortium includes Peter Barnes and Omar Usmani of Imperial College London, Ben Forbes of King’s College, and Rob Price of the University of Bath.
Prosonix uses proprietary engineering techniques to create particles containing predetermined ratios of active ingredients, and the project will evaluate various combinations of LAMAs, LABAs, and inhaled corticosteroids. In addition to development of the MCP platform, the funding will also be used for development of living tissue lung models for the assessment of inhaled combination drugs.
By the end of the year, Prosonix says, it plans to choose one or more of the MCP candidates to begin formal preclinical/proof of concept studies.
Prosonix CEO David Hipkiss commented, “We believe that our revolutionary MCP particle engineering approach to combination respiratory medicines could lead to a future range of clinically differentiated and cost-effective asthma and COPD therapies. We are delighted to accept this grant award from the Biomedical Catalyst and to be working with some of the world’s leading academic researchers in the respiratory medicine and inhaled drug delivery fields to further support the development of our technology enabled products.”
Read the Prosonix press release.
